{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T09:49:44Z","timestamp":1725875384017},"reference-count":15,"publisher":"American Society of Consultant Pharmacists","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2013,4,1]]},"DOI":"10.4140\/tcp.n.2013.243","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T06:20:31Z","timestamp":1365056431000},"page":"243-246","source":"Crossref","is-referenced-by-count":8,"title":["Galantamine-Associated Nightmares and Anxiety"],"prefix":"10.4140","volume":"28","author":[{"given":"Jason M.","family":"Corbo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie N.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason M.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2013,4,3]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012;8:131-68.","DOI":"10.1016\/j.jalz.2012.02.001"},{"key":"2","first-page":"5","article-title":"American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias","volume":"164","author":"PV Rabins","year":"2007","journal-title":"Am J Psychiatry"},{"key":"3","unstructured":"Razadyne ER\/Razadyne (package insert). Titusville, NJ: Ortho- McNeil-Janssen Pharmaceuticals, Inc; 2008."},{"key":"4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.smrv.2005.06.001","article-title":"Nightmares: from anxiety symptom to sleep disorder","volume":"10","author":"VI Spoormaker","year":"2006","journal-title":"Sleep Med Rev"},{"key":"5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"CA Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5664\/jcsm.27883","article-title":"Best practice guide for the treatment of nightmare disorder in adults","volume":"6","author":"RN Aurora","year":"2010","journal-title":"J Clin Sleep Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1532-5415.2009.02157.x","article-title":"An unusual case of nightmares with galantamine","volume":"57","author":"A Iraqi","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1185\/030079904125003214","article-title":"Examination of nighttime sleep-related problems during double-blind, placebocontrolled trials of galantamine in patients with Alzheimer's disease","volume":"20","author":"SM Stahl","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"9","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1185\/03007990802522397","article-title":"Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine","volume":"24","author":"A Nieoullon","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10","unstructured":"Aricept (package insert). Woodcliff Lake, NJ: Eisai Co., Ltd; 2010."},{"key":"11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1532-5415.1998.tb01033.x","article-title":"Aricept-induced nightmares in Alzheimer's disease: 2 case reports","volume":"46","author":"JS Ross","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"12","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/026988110001400410","article-title":"Adverse effects associated with the use of donepezil in general practice in England","volume":"14","author":"NR Dunn","year":"2000","journal-title":"J Psychopharmacol"},{"key":"13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1742-1241.2002.tb11294.x","article-title":"A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine with mild to moderate Alzheimer's disease","volume":"56","author":"DG Wilkinson","year":"2002","journal-title":"Int J Clin Pract"},{"key":"14","unstructured":"Exelon Patch (package insert). East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009."},{"key":"15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0006-3223(00)01101-X","article-title":"Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease","volume":"49","author":"J Coyle","year":"2001","journal-title":"Biol Psychiatry"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T20:38:41Z","timestamp":1688157521000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2013\/00000028\/00000004\/art00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,1]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4,1]]}},"alternative-id":["W3823741624033W0"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2013.243","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4,1]]}}}